News | January 18, 2018

Pharnext's Pivotal Phase 3 Trial PLEO-CMT To Be Featured At The 22nd Edition Of The Francophone Peripheral Nerve Society Conference

Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, recently announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France).

Details of the presentation are as follows:

Date Time Session
Friday January 26, 2018 From 3:03 to 3:15pm CET

Selected Oral Communications Session

  • Title: Status of the Pivotal Phase III Study (PLEO-CMT) Assessing the Efficacy and Safety of PXT3003 in the Treatment of Adult Patients with Charcot-Marie-Tooth type 1A
  • Speaker : Prof. Shahram Attarian (Marseille)

For more information, visit

SOURCE: Pharnext